Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00648661 | Food Study of Escitalopram Oxalate Tablets 20 mg to Lexapro® Tablets 20 mg | PHASE1 | COMPLETED | 35 | — | — | Sep 1, 2004 | Oct 1, 2004 | Apr 24, 2024 | 1 | United States |
| NCT00648570 | Fasting Study of Escitalopram Oxalate Tablets 20 mg and Lexapro® Tablets 20 mg | PHASE1 | COMPLETED | 37 | — | — | Aug 1, 2004 | Oct 1, 2004 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Escitalopram Oxalate Tablets 20 mg |
| 2 | ACTIVE_COMPARATOR | Lexapro® Tablets 20 mg |
| Name | Type | Description |
|---|---|---|
| Escitalopram Oxalate Tablets 20 mg | DRUG | 20mg, single dose fed |
| Lexapro® Tablets 20 mg | DRUG | 20mg, single dose fed |
| Lexapro® Tablets (20 mg | DRUG | 20mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum β-human chorionic gonadotropin (β-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening p...